Paper8658136
Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis.
Sherman DR and 6 others. Science, 1996. Cited by 351 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Papers, record 8658136. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8658136
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antitubercular Agents | Major topic |
| Bacterial Proteins | Major topic |
| Isoniazid | Major topic |
| Mycobacterium tuberculosis | Major topic |
| Oxidoreductases | Major topic |
| Amino Acid Sequence | |
| Base Sequence | |
| Cloning, Molecular | |
| DNA, Bacterial | |
| Drug Resistance, Microbial | |
| Drug Synergism | |
| Enzyme Induction | |
| Gene Expression Regulation, Bacterial | |
| Hydrogen Peroxide | |
| Molecular Sequence Data | |
| Mutation | |
| Mycobacterium bovis | |
| Peroxidases | |
| Peroxiredoxins | |
| Promoter Regions, Genetic |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Z01 AI000783 | Intramural NIH HHS | United States | Z01AI000783 | PubMed |
Source NIH RePORTER
Cited by177
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 351 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,610,698 | The bacterial pH gradient contributes to persistence in Mycobacterium tuberculosis. | mBio | 2026 | https://conductscience.org/library/papers/42610698 | PubMed |
| 41,859,070 | Mutations in oxyR and oxyR-ahpC Interogenic Region in Isoniazid-Resistant Mycobacterium tuberculosis Clinical Isolates from Chongqing, China. | Infect Drug Resist | 2026 | https://conductscience.org/library/papers/41859070 | PubMed |
| 41,856,489 | Prevalence and resistance spectrum of ahpC mutations in isoniazid-resistant Mycobacterium tuberculosis isolates. | Microbiol Spectr | 2026 | https://conductscience.org/library/papers/41856489 | PubMed |
| 41,809,859 | Multicentre field evaluation of Xpert MTB/XDR in sub-Saharan Africa. | ERJ Open Res | 2026 | https://conductscience.org/library/papers/41809859 | PubMed |
| 41,207,943 | Key Proteins and Enzymatic Mechanisms Underlying Drug Resistance in Mycobacterium tuberculosis. | Adv Exp Med Biol | 2026 | https://conductscience.org/library/papers/41207943 | PubMed |
| 41,033,137 | Evaluating selection at intermediate scales within genes provides robust identification of genes under positive selection in M. tuberculosis clinical isolates. | Tuberculosis (Edinb) | 2025 | https://conductscience.org/library/papers/41033137 | PubMed |
| 41,001,543 | The pH gradient contributes to persistence in Mycobacterium tuberculosis. | Res Sq | 2025 | https://conductscience.org/library/papers/41001543 | PubMed |
| 40,580,943 | Fitness Effect of the Isoniazid Resistance Mutation S315T of the Catalase-Peroxidase Enzyme KatG of Mycobacterium tuberculosis. | Genome Biol Evol | 2025 | https://conductscience.org/library/papers/40580943 | PubMed |
| 40,462,945 | Evaluating selection at intermediate scales within genes provides robust identification of genes under positive selection in M. tuberculosis clinical isolates. | bioRxiv | 2025 | https://conductscience.org/library/papers/40462945 | PubMed |
| 40,332,486 | Insights into Active Site Cysteine Residues in Mycobacterium tuberculosis Enzymes: Potential Targets for Anti-Tuberculosis Intervention. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40332486 | PubMed |
| 40,078,052 | Multi-drug resistance and compensatory mutations in Mycobacterium tuberculosis in Vietnam. | Trop Med Int Health | 2025 | https://conductscience.org/library/papers/40078052 | PubMed |
| 40,032,816 | Multivariable regression models improve accuracy and sensitive grading of antibiotic resistance mutations in Mycobacterium tuberculosis. | Nat Commun | 2025 | https://conductscience.org/library/papers/40032816 | PubMed |
| 39,819,645 | Altering the redox status of Chlamydia trachomatis directly impacts its developmental cycle progression. | Elife | 2025 | https://conductscience.org/library/papers/39819645 | PubMed |
| 39,537,610 | Catalase activity deficiency sensitizes multidrug-resistant Mycobacterium tuberculosis to the ATP synthase inhibitor bedaquiline. | Nat Commun | 2024 | https://conductscience.org/library/papers/39537610 | PubMed |
| 39,537,607 | Whole genome CRISPRi screening identifies druggable vulnerabilities in an isoniazid resistant strain of Mycobacterium tuberculosis. | Nat Commun | 2024 | https://conductscience.org/library/papers/39537607 | PubMed |
| 38,811,658 | Large-scale statistical analysis of Mycobacterium tuberculosis genome sequences identifies compensatory mutations associated with multi-drug resistance. | Sci Rep | 2024 | https://conductscience.org/library/papers/38811658 | PubMed |
| 38,587,412 | Transcriptomic responses to antibiotic exposure in Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 2024 | https://conductscience.org/library/papers/38587412 | PubMed |
| 38,509,362 | Compensatory evolution in NusG improves fitness of drug-resistant M. tuberculosis. | Nature | 2024 | https://conductscience.org/library/papers/38509362 | PubMed |
| 38,473,077 | Genomic and Proteomic Analyses of Extracellular Products Reveal Major Virulence Factors Likely Accounting for Differences in Pathogenicity to Bivalves between Vibrio mediterranei Strains. | Animals (Basel) | 2024 | https://conductscience.org/library/papers/38473077 | PubMed |
| 38,466,098 | Genetic mechanisms of co-emergence of INH-resistant Mycobacterium tuberculosis strains during the standard course of antituberculosis therapy. | Microbiol Spectr | 2024 | https://conductscience.org/library/papers/38466098 | PubMed |
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| GENBANK | U18264 |
Source GENBANK
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8658136
GET https://conductscience.org/api/papers/v1/8658136/cited_by?page=2